A humanized anti-trophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa monoclonal antibody is combined with SN-38, the active metabolite of the topoisomerase inhibitor irinotecan, via a proprietary hydrolyzable linker to form Sacituzumab Govitecan, an antibody-drug conjugate
Parenteral administration should always follow proper aseptic technique, and the solution should be inspected for particulates or discoloration before use
Individual responses vary, and treatment outcomes depend on multiple factors, including adherence to the prescribed plan and recommended lifestyle modifications
This guide explores how these two powerhouses interact, the best way to time your doses, and how they support an active, high-impact lifestyle
Individual variation plays a significant role in how people respond to medication combinations
We go further because weight is almost never just about weight